Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00308516 · ClinicalTrials.gov registry record · Phase 2
5-Fluorouracil, Bevacizumab, and Radiation Followed by Modified FOLFOX6 and Bevacizumab in Stage II/III Rectal Cancer
A Phase 2 study of Colorectal Cancer and Rectal Cancer, sponsored by SCRI Development Innovations.
- Completed
- Registry status
- Phase 2
- Development phase
- 66
- Enrollment target
- 14
- Study locations
NCT00308516 is a Phase 2 study of Colorectal Cancer and Rectal Cancer that has completed, run by SCRI Development Innovations. The registered enrollment target is 66 participants, below the 1,511-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (96% lower). The trial reports 14 study locations across 10 states.
The verdict
NCT00308516, a Phase 2 study of Colorectal Cancer and Rectal Cancer, has completed, sponsored by SCRI Development Innovations.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 66 participants
- Enrollment target
- 14
- Study locations
Study Summary
This phase II trial will investigate the combination of adjuvant 5-fluorouracil, radiation, and bevacizumab in patients with stage II and III rectal cancer, followed by FOLFOX6 and bevacizumab. Fluorouracil (FU) has proven to be an effective and safe regimen in the treatment of stage II and III rectal cancer. Recent evidence has proven fluorouracil/leucovorin (FL) in combination with bevacizumab is superior to FL alone and when combined with irinotecan is superior to (irinotecan plus fluorouracil/leucovorin (IFL) alone. This trial will be one of the first clinical trials to evaluate a combination of targeted therapy, radiation, and chemotherapy in the adjuvant treatment of a common solid tumor.
Conditions Studied
Interventions
- DRUG Bevacizumab
- DRUG Leucovorin
- DRUG Oxaliplatin
- DRUG 5-Fluorouracil
- PROCEDURE Radiation Therapy
Study Locations (14)
Florida
- Florida Cancer Specialists - Fort Myers
- Integrated Community Oncology Network - Jacksonville
- Watson Clinic Center for Cancer Care and Research - Lakeland
Georgia
- Northeast Georgia Medical Center - Gainesville
- Wellstar Cancer Research - Marietta
Tennessee
- Chattanooga Oncology Hematology Associates - Chattanooga
- Tennessee Oncology - Nashville
Alabama
- Northeast Alabama Regional Medical Center - Anniston
Arkansas
- Northeast Arkansas Clinic - Jonesboro
Kentucky
- Consultants in Blood Disorders and Cancer - Louisville
Pennsylvania
- Consultants in Medical Oncology and Hematology - Drexel Hill
South Carolina
- Spartanburg Regional Medical Center - Spartanburg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2006-03 |
| Est. Completion | 2012-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00308516
The ClinicalTrials.gov registry entry for NCT00308516 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,511-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (96% lower). The listed sponsor is SCRI Development Innovations, which has 146 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Colorectal Cancer appearing as the primary indexed condition, and to 5 interventions - of which Bevacizumab is the first listed.
NCT00308516 reports 14 study locations spanning 10 distinct geographic areas - top geographies include Florida, Georgia, Tennessee.
Frequently Asked Questions
What is clinical trial NCT00308516 about?
NCT00308516 is a clinical study titled "5-Fluorouracil, Bevacizumab, and Radiation Followed by Modified FOLFOX6 and Bevacizumab in Stage II/III Rectal Cancer". This phase II trial will investigate the combination of adjuvant 5-fluorouracil, radiation, and bevacizumab in patients with stage II and III rectal cancer, followed by FOLFOX6 and bevacizumab. Fluorouracil (FU) has proven to be an effective and safe regimen in the treatment of stage II and III rect...
What is the current status of trial NCT00308516?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 66 participants. The study started on 2006-03. Estimated completion is 2012-02.
What conditions does trial NCT00308516 study?
This clinical trial studies the following conditions: Colorectal Cancer, Rectal Cancer, Cancer of the Rectum.
What interventions are being tested in trial NCT00308516?
The interventions under investigation include: Bevacizumab (DRUG), Leucovorin (DRUG), Oxaliplatin (DRUG), 5-Fluorouracil (DRUG), Radiation Therapy (PROCEDURE).
Who is sponsoring clinical trial NCT00308516?
This trial is sponsored by SCRI Development Innovations, which has 146 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00308516 being conducted?
This trial has 14 study locations across Alabama, Arkansas, Florida, Georgia, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease
RECRUITING · Phase 2
-
A Study of Single Fraction Stereotactic Body Radiation Therapy (SBRT) Guided by Magnetic Resonance Imaging (MRI) in People With Liver Metastasis From Colorectal Cancer
RECRUITING · Phase 2
-
TAS-102 With or Without Celecoxib in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy
RECRUITING · Phase 2
-
A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy
RECRUITING · Phase 2
-
A Study of IBI363 in Subjects with Advanced Solid Malignancies
RECRUITING · Phase 2
-
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.